Denali Therapeutics (DNLI) Current Leases: 2019-2025
Historic Current Leases for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2025 value amounting to $9.2 million.
- Denali Therapeutics' Current Leases rose 14.04% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 14.04%. This contributed to the annual value of $8.3 million for FY2024, which is 14.44% up from last year.
- Per Denali Therapeutics' latest filing, its Current Leases stood at $9.2 million for Q3 2025, which was up 3.30% from $8.9 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Current Leases registered a high of $9.2 million during Q3 2025, and its lowest value of $4.9 million during Q1 2021.
- Its 3-year average for Current Leases is $7.8 million, with a median of $7.8 million in 2024.
- In the last 5 years, Denali Therapeutics' Current Leases spiked by 34.58% in 2022 and then dropped by 0.79% in 2023.
- Over the past 5 years, Denali Therapeutics' Current Leases (Quarterly) stood at $5.5 million in 2021, then surged by 34.20% to $7.3 million in 2022, then fell by 0.79% to $7.3 million in 2023, then rose by 14.44% to $8.3 million in 2024, then grew by 14.04% to $9.2 million in 2025.
- Its last three reported values are $9.2 million in Q3 2025, $8.9 million for Q2 2025, and $8.6 million during Q1 2025.